Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it

The FDA is­sued Spring­Works Ther­a­peu­tics a Form 483 on March 31, say­ing that the com­pa­ny’s own clin­i­cal tri­al pro­to­cols were not fol­lowed. But Spring­Works COO